© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | S. Kroll
Articles
Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data
March 01, 2001
ByJ. P. Leonard|A. D. Zelenetz|J. M. Vose|J. A. Radford|R. L. Wahl|A. Rohatiner|S. Kroll|R. Stagg|K. Nadeau|N. Valente|M. S. KaminskiTositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
March 01, 2000
ByJ. M. Vose|A. D. Zelenetz|A. Rohatiner|S. Knox|R. Stagg|S. Kroll|G. Tidmarsh|M. S. KaminskiIodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-
Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience
March 01, 2000
ByM. S. Kaminski|O. W. Press|T. A. Lister|N. K. Valente|S. Kroll|G. TidmarshTositumomab and iodine -131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of low-grade or transformed, low-grade non-Hodgkin’s lymphoma (NHL).